Price Alert

BioXcel Therapeutics Inc. (BTAI)

NASDAQ: BTAI · Real-Time Price · USD

5.47

0.72 (15.16%)

At close: Aug 15, 2025, 3:59 PM

6.01

9.87%

After-hours: Aug 15, 2025, 07:07 PM EDT

15.16% (1D)

Bid	6
Market Cap	33.13M
Revenue (ttm)	1.85M
Net Income (ttm)	-40.06M
EPS (ttm)	-11.9
PE Ratio (ttm)	-0.46
Forward PE	-1.03
Analyst	Buy

Ask	6.03
Volume	7,128,446
Avg. Volume (20D)	7,433,741
Open	4.65
Previous Close	4.75
Day's Range	4.10 - 5.48
52-Week Range	1.17 - 13.36
Beta	0.06

About BTAI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BTAI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BTAI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

BioXcel Therapeutics has released their quartely earnings on Aug 12, 2025:

Revenue of $120K misses estimates by $107.5K, with -89.13% YoY decline.

EPS of -2.45 misses estimates by -0.59, with 27.08% YoY growth.

Next Earnings Release

BioXcel Therapeutics Inc. is scheduled to release its earnings on Nov 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+18.48%

Therapeutics shares are trading higher after the c... Unlock content with Pro Subscription

2 weeks ago

+4.58%

BioXcel Therapeutics shares are trading higher after the company completed the last patient visit in its SERENITY at-home pivotal Phase 3 safety trial.

News

3 days ago · zacks.com

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $2.45 per share versus the Zacks Consensus Estimate of a loss of $2.3. This compares to a loss of $3.36 per share a year ago.

2 months ago · https://www.defenseworld.net

Squarepoint Ops LLC Acquires 48,336 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)

Squarepoint Ops LLC grew its stake in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) by 203.9% during the fourth quarter, according to the company in its most recent 13F filing...